ta in COVID-19 patients show diffuse alveolar damage, closely related to ARDS [[10], [11], [12]]. The clinical relevance of COVID-19-associated pulmonary aspergillosis (CAPA) as well as survival benefit with antifungal treatment and associated mortality are under deba